menu
    • menu

    Company profile for Neurenati Therapeutics

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Neurenati Therapeutics stands out as a pioneering biotechnology company dedicated to the development of an innovative treatment for Hirschsprung's disease. The collaboration between Nicolas Pilon, an expert in rare diseases, and Rodolphe Soret, a specialist in neuro-gastroenterology, has resulted in the creation of a promising treatment. Supported by serial entrepreneur Maxime Ranger and a team of experts in medicine, gastroen...
    Neurenati Therapeutics stands out as a pioneering biotechnology company dedicated to the development of an innovative treatment for Hirschsprung's disease. The collaboration between Nicolas Pilon, an expert in rare diseases, and Rodolphe Soret, a specialist in neuro-gastroenterology, has resulted in the creation of a promising treatment. Supported by serial entrepreneur Maxime Ranger and a team of experts in medicine, gastroenterology, and clinical trials focused on rare diseases, Neurenati Therapeutics is committed to advancing this innovative treatment and ultimately making it available in clinical practice.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Neurenati TherapeuticsCanada Flag
    Country
    Country
    Canada
    Address
    Address
    Montreal, Quebec H3B 1S6
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.neurenati.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/neurenati/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    neurenati therapeutics welcomes Dr. guay and di lorenzo to board
    neurenati therapeutics welcomes Dr. guay and di lorenzo to board

    11 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251211193079/en/Neurenati-Therapeutics-Welcomes-Dr-Daniel-Guay-to-Its-Board-of-Directors-and-Dr-Carlo-Di-Lorenzo-to-Its-Scientific-and-Clinical-Advisory-Board

    BUSINESSWIRE
    11 Dec 2025
    Share Share
    Neurenati's NEU-001 Receives EMA Orphan Drug Designation
    Neurenati's NEU-001 Receives EMA Orphan Drug Designation

    28 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251028497876/en/The-EMA-Grants-Orphan-Drug-Designation-to-Neurenatis-NEU-001-for-the-Treatment-of-Hirschsprung-Disease

    BUSINESSWIRE
    28 Oct 2025
    Share Share
    Neurenati's First Scientific Advisory Board Meeting for NEU-001
    Neurenati's First Scientific Advisory Board Meeting for NEU-001

    10 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250610768887/en/Neurenati-Announces-its-First-Scientific-and-Clinical-Advisory-Board-Meeting-with-KOLs-to-Advance-the-Development-of-NEU-001-a-Promising-Cure-for-Hirschsprung-Disease

    BUSINESSWIRE
    10 Jun 2025
    Share Share
    FDA Grants Orphan, Rare Pediatric Status To NEU-001 For Hirschsprung
    FDA Grants Orphan, Rare Pediatric Status To NEU-001 For Hirschsprung

    04 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250304216736/en

    BUSINESSWIRE
    04 Mar 2025
    Share Share
    Neurenati Therapeutics: Board Strengthening with Dr. Cohard-Radice
    Neurenati Therapeutics: Board Strengthening with Dr. Cohard-Radice

    08 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240508400931/en

    BUSINESSWIRE
    08 May 2024
    Share Share
    Neurenati Therapeutics Raises $1.7M In Second Seed Funding Round
    Neurenati Therapeutics Raises $1.7M In Second Seed Funding Round

    18 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240417054719/en

    BUSINESSWIRE
    18 Apr 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search